Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $67.19 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.
Shares of NASDAQ:TMCI opened at $10.05 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.98 and a current ratio of 4.12. The firm has a fifty day moving average price of $8.61 and a 200 day moving average price of $7.08. Treace Medical Concepts has a fifty-two week low of $3.92 and a fifty-two week high of $15.44. The firm has a market cap of $626.12 million, a price-to-earnings ratio of -10.15 and a beta of 0.75.
TMCI has been the subject of a number of research reports. Lake Street Capital initiated coverage on shares of Treace Medical Concepts in a research report on Tuesday, December 31st. They set a "buy" rating and a $14.50 target price for the company. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $8.00 price target on shares of Treace Medical Concepts in a research note on Tuesday, December 17th. BTIG Research raised shares of Treace Medical Concepts from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research note on Tuesday, February 4th. Truist Financial upped their price target on shares of Treace Medical Concepts from $7.00 to $8.40 and gave the company a "hold" rating in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus increased their target price on shares of Treace Medical Concepts from $7.00 to $8.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Treace Medical Concepts presently has a consensus rating of "Hold" and a consensus target price of $9.99.
Get Our Latest Stock Report on Treace Medical Concepts
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.